Cullinan Therapeutics (CGEM)
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages...
- Open
- 20.620
- High
- 21.000
- Low
- 18.775
- Prev. Close
- 19.600
- Volume
- 321.04K
- Turnover
- 6.44M
- Avg Price
- 20.074
- Bid/Ask Ratio
- 81.82%
- Amplitude
- 11.35%
- 52wk High
- 21.000
- Volume Ratio
- 9.46
- Turnover Ratio
- 0.66%
Cullinan Therapeutics Analyst Rating
View moreForecast & Rating
Aug 13, 2026Price forecast
$32.0959.46%
Forecast & RatingStrong buy
12analysts
- Strong buy91.67%
- Buy8.33%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Market Beat · 5 hours ago
Cullinan Therapeutics, Inc. $CGEM Shares Bought by The Manufacturers Life Insurance Company
- benzinga_article · 1 hour ago
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- rttnews · 2 hours ago
Show Me The Money: Did You Miss CGEM's Rally? Here's What Comes Next
- Tip Ranks · 3 hours ago
Cullinan Reports Positive Phase 3 Zipalertinib Lung Cancer Data
- Market Beat · 7 hours ago
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
- StockTitan · 22 hours ago
Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer | CGEM Stock News
